Macrogenics (NASDAQ: MGNX) reported Q3 EPS of $0.27, $0.68 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $53 million versus the consensus estimate of $28.72 million.

Cash Runway Guidance: MacroGenics anticipates that its cash, cash equivalents and marketable securities balance of $146.4 million as of September 30, 2025, in addition to subsequent receipt of $75.0 million in partnering payments from Sanofi and Gilead, plus projected and anticipated future payments from partners and anticipated savings from the Company’s ongoing cost-reduction initiatives, is expected to support its cash runway into late 2027.

For earnings history and earnings-related data on Macrogenics (MGNX) click here.